. Although such treatment ceased in 1985, iatrogenic CJD (iCJD) continues to emerge because of the prolonged incubation periods seen in human prion infections. Unexpectedly, in an autopsy study of eight individuals with iCJD, aged 36-51 years, in four we found moderate to severe grey matter and vascular amyloid-b (Ab) pathology. The Ab deposition in the grey matter was typical of that seen in Alzheimer's disease and Ab in the blood vessel walls was characteristic of cerebral amyloid angiopathy 3 and did not co-localize with prion protein deposition. None of these patients had pathogenic mutations, APOE e4 or other high-risk alleles 4 associated with early-onset Alzheimer's disease. Examination of a series of 116 patients with other prion diseases from a prospective observational cohort study 5 showed minimal or no Ab pathology in cases of similar age range, or a decade older, without APOE e4 risk alleles. We also analysed pituitary glands from individuals with Ab pathology and found marked Ab deposition in multiple cases. Experimental seeding of Ab pathology has been previously demonstrated in primates and transgenic mice by central nervous system or peripheral inoculation with Alzheimer's disease brain homogenate [6] [7] [8] [9] [10] [11] . The marked deposition of parenchymal and vascular Ab in these relatively young patients with iCJD, in contrast with other prion disease patients and population controls, is consistent with iatrogenic transmission of Ab pathology in addition to CJD and suggests that healthy exposed individuals may also be at risk of iatrogenic Alzheimer's disease and cerebral amyloid angiopathy. These findings should also prompt investigation of whether other known iatrogenic routes of prion transmission may also be relevant to Ab and other proteopathic seeds associated with neurodegenerative and other human diseases.
Human transmission of prion disease has occurred as a result of a range of medical and surgical procedures worldwide as well as by endocannibalism in Papua New Guinea, with incubation periods that can exceed five decades 12, 13 . A well-recognized iatrogenic route of transmission was by treatment of persons of short stature with preparations of human growth hormone, extracted from large pools of cadaver-sourced pituitary glands, some of which were inadvertently prion-contaminated. Such treatments commenced in 1958 and ceased in 1985 following the reports of the occurrence of CJD amongst recipients. A review of all 1,848 patients who were treated with cadavericderived human growth hormone (c-hGH) in the United Kingdom from 1959 through 1985 found that 38 had developed CJD by the year 2000 with a peak incubation period of 20 years 1 . Multiple preparations using different extraction methods were used over this period and patients received batches from several preparations. One preparation (Wilhelmi) was common to all patients who developed iCJD and size-exclusion chromatography, used in non-Wilhelmi preparation methods, may have reduced prion contamination 1 . As of 2012, a total of 450 cases of iatrogenic CJD have been recognized worldwide after treatment with c-hGH or gonadotropin (226 cases), transplantation of dura mater (228) or cornea (2), and neurosurgery (4) or electroencephalography recording using invasive medical devices (2) 2 . In France, 119/1,880 (6.3%) recipients developed iCJD, in the UK 65/1,800 (3.6%) and in the USA 29/7,700 (0.4%) 2,14 . Since 2008, most UK patients with prion disease have been recruited into the National Prion Monitoring Cohort study 5 , including 22 of 24 recent patients with iatrogenic CJD (iCJD) related to treatment with c-hGH over this period, all of whom necessarily have very long incubation periods. Of this group of patients with iCJD, eight patients (referenced no.s 1-8, Supplementary Information) aged 36-51 years, with an incubation period from first treatment to onset of 27.9-38.9 years (mean 33 years) and from last treatment to onset of 18.8-30.8 years (mean 25.5 years), underwent autopsy with extensive brain tissue sampling at our hospital. In all eight brain samples we confirmed prion disease with abnormal prion protein labelling of the neuropil, perineuronal network and in most cases microplaques as described previously [15] [16] [17] . However, four (no.s 4, 5, 6, 8) of the eight patients with iCJD also showed substantial amyloid-b (Ab) deposition in the central nervous system parenchyma by histology ( Fig. 1) and immunoblotting (Fig. 2) . A further two brain samples (no.s 1, 3) had focal Ab pathology in one of the brain regions; one showed Ab entrapment in PrP plaques and only one was entirely negative for Ab. Furthermore, there was widespread cortical and leptomeningeal cerebral Ab angiopathy (CAA) 3 in three patients (no.s 4, 6, 8) and focal CAA in one patient (no. 5) (Fig. 1) . Such pathology is extremely rare in this age range, 10/290 in the equivalent 36-50 year age strata without CJD 18 , P 5 0.0002, Fisher's test. None of our patients with iCJD had pathogenic mutations in the prion protein gene (PRNP). We used a custom next generation sequencing panel 4 to exclude mutation in any of 16 other genes associated with early-onset Alzheimer's disease, CAA, or other neurodegenerative disorders, and none carried APOE e4 or TREM2 R47H alleles (Supplementary Table 2 ). Although such observations are unprecedented in our wide experience of human prion diseases, we nevertheless considered whether prion disease itself might predispose to, or accelerate, Ab pathology, for example by cross-seeding of protein aggregation or overload of clearance mechanisms for misfolded proteins. We therefore compared the Ab pathology in the iCJD cohort with that of a cohort of 116 patients with other prion diseases who had undergone autopsy: sporadic CJD (sCJD) (n 5 85, age 42-83), variant CJD (n 5 2, age 25 and 36) and inherited prion diseases (IPD) (n 5 29, age 29-86). None of the patients in the control cohorts had comparable Ab pathology (Consortium to Establish a Registry for Alzheimer's disease (CERAD) score, P 5 0.001, CAA, P 5 0.005, topographical Ab score P 5 0.02, and cumulative Ab score P 5 0.02 (rank sum test) and digital Ab quantification P 5 0.04 (t-test); all restricted to the strata aged 36-51 years (n 5 19)) (Fig. 3 , and Extended Data Figs 1 and 2 show similar results in adjusted analyses in the full cohort). Indeed none of 35 prion cases aged 52-60 had significant Ab pathology, with the exception of two cases at ages 57 and 58 positive for APOE e4 alleles. Instead, the sCJD cohort shows Ab pathology in parenchyma and blood vessels to a similar extent/severity as seen in iCJD, only in a much older age group (Extended Data Figs 1 and 2), in keeping with the chance coincidence of late-onset Ab pathology and sCJD as previously documented in a large study of 110 sCJD patients and 110 age-matched controls aged 27-84 (ref. 19 ) and a study . We examined 55 pituitary glands, 6 from patients without, and 49 from patients with cerebral Ab pathology, and found in the latter group seven samples containing Ab, confirming frequent Ab in pituitaries of patients with Alzheimer's disease-like pathology 20 ( Fig. 1i and Extended Data Fig. 3 ), consistent with the hypothesis that Ab seeds have been iatrogenically transmitted to these patients with iCJD.
There has been longstanding interest as to whether other neurodegenerative diseases associated with the accumulation of aggregates of misfolded host proteins or amyloids might be transmissible in a 'prionlike' fashion 21, 22 . Experimental seeding of Ab pathology has previously been demonstrated in primates and transgenic mice by central nervous system inoculation with Alzheimer's disease brain homogenate [6] [7] [8] [9] [10] . Of particular interest with respect to our findings is that peripheral (intraperitoneal) inoculation with Alzheimer's disease brain extract into APP23 (ref. 11) transgenic mice has been demonstrated. While ageing APP23 mice show mostly parenchymal deposits, the intraperitoneallyseeded mice showed predominantly CAA, a feature seen in patients with iCJD who had significant Ab pathology. This experimental study and our findings suggest that there are mechanisms to allow the transport of Ab seeds as well as prions (and possibly other proteopathic seeds such as tau 23 ) from the periphery to the brain 24, 25 . While less than 4% of UK c-hGH treated individuals have developed iCJD, one out of eight patients with iCJD had focal, and three had widespread, moderate or severe CAA. Four patients had widespread parenchymal Ab pathology and two further patients had focal cortical Ab deposits. This might suggest that healthy individuals exposed to c-hGH are at high risk of developing early-onset Ab pathology as this cohort ages.
Although none of the iCJD cases with Ab pathology had hyperphosphorylated tau neurofibrillary tangle pathology characteristic of Alzheimer's disease, it is possible that the full neuropathology of Alzheimer's disease would have developed had these individuals not succumbed to prion disease at these relatively young ages. An earlier study concluded that c-hGH recipients did not seem to be at increased risk of Alzheimer's disease, but this was based on death certificates only without autopsy data 20 . However, the severe CAA seen in the patients with iCJD in our study is unquestionably concerning and individuals with such pathology would be at increasing risk of cerebral haemorrhages had they lived longer. At-risk individuals, including patients who had received dura mater grafts 26 could be screened by magnetic resonance imaging (MRI) for CAA-related pathologies (such as microbleeds) and by positron emission tomography (PET) for Ab deposition 27 . It is possible, however, that prions and Ab seeds co-purify in the extraction methods used to prepare c-hGH, which might mean that there would be a relatively higher occurrence of Ab pathology in those with iatrogenic prion infection. Analysis of any residual archival batches of c-hGH for both prions and Ab seeds might be informative in this regard 2 . While our data argue against cross seeding, we cannot formally exclude the possibility that prions somehow seed Ab deposition but do not co-localize with Ab deposits. While there is no suggestion that Alzheimer's disease is a contagious disease and no supportive evidence from epidemiological studies that Alzheimer's disease is transmissible, notably by blood transfusion 28, 29 , our findings should prompt consideration of whether other known iatrogenic routes of prion transmission, including surgical instruments and blood products, may also be relevant to Ab and other proteopathic seeds seen in neurodegenerative diseases. Ab seeds are known, like prions, to adhere to metal surfaces and to resist formaldehyde inactivation and conventional hospital sterilisation 30 .
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. 
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METHODS
No statistical methods were used to predetermine sample size, the experiments were not randomized and the investigators were not blinded to allocation during experiments and outcome assessment. Patient recruitment and genotyping. A national referral system for prion diseases was established by the Chief Medical Officer in the UK in 2004. UK neurologists were asked to refer all patients with suspected prion disease jointly to the National CJD Research and Surveillance Unit in Edinburgh and the NHS National Prion Clinic (NPC) in London. All patients with possible CJD who had received cadaver-derived growth hormone were referred to the NHS National Prion Clinic (London, UK) and since 2008 were recruited into the National Prion Monitoring Cohort study. Next-generation sequencing to exclude mutations known to be causal of Ab pathology. Deep next-generation sequencing using a custom panel was performed as described previously 31 . Analysis was done using NextGENe and Geneticist Assistant software (Softgenetics, USA). Variants were assessed for pathogenicity by reference to the published literature, control population allele frequencies (our primary database for allele frequency was the Broad Institute's ExAC browser (http://exac.broadinstitute.org/)) and in silico predictive tools. The analysis methodology has been validated for the detection of APP duplication 31 , which was important to exclude. No causal mutations for dementia or Ab pathology were detected, see Supplementary Table 2 . As expected, several rare variants were detected which may modify the risk of various neurodegenerative diseases, see Supplementary Table 2 . Autopsies and tissue preparation. Autopsies were carried out in a post mortem room designated for high risk autopsies. Informed consent to use the tissue for research was obtained in all cases. Ethical approval for these studies was obtained from the Local Research Ethics Committee of the UCL Institute of Neurology/ National Hospital for Neurology and Neurosurgery. The anterior frontal, temporal, parietal and occipital cortex and the cerebellum (at the level of dentate nucleus) were dissected during the post mortem procedure and frozen. Samples of the following areas were taken and analysed: frontal, temporal, parietal, occipital, posterior frontal cortex including motor strip, basal ganglia, thalamus, hippocampus, brain stem including midbrain, and cerebellar hemisphere and vermis. Pituitary glands were taken in all cases.
Tissue samples were immersed in 10% buffered formalin and prion infectivity was inactivated by immersion into 98% formic acid for one hour. Tissue samples were processed to paraffin wax and tissue sections were routinely stained with haematoxylin and eosin. Antibodies and immunohistochemistry. The following antibodies were used: Anti-PrP ICSM35 (D-Gen Ltd, London, UK 32,33 1:1,000), Anti-phospho-Tau (AT-8, Innogenetics, 1:100) and anti-bA4 (DAKO 6F3D, 1:50). ICSM35 was stained on a Ventana Benchmark or Discovery automated immunohistochemical staining machine (ROCHE Burgess Hill, UK); bA4 and Tau were stained on a LEICA BondMax (LEICA Microsystems) or a Ventana automated staining instrument following the manufacturer's guidelines, using biotinylated secondary antibodies and a horseradish-peroxidase-conjugated streptavidin complex and diaminobenzidine as a chromogen. Immunoblot detection of Ab in iCJD brain. Biochemical studies were carried out in a microbiological containment level 3 facility with strict adherence to safety protocols. Frozen brain tissue was available from seven of eight patients with growth hormone iCJD (cases 1 and 3-8). 10% (w/v) brain homogenates (grey matter; frontal cortex) were prepared in Dulbecco's PBS lacking Ca 21 or Mg 21 ions using tissue grinders as described previously 34 . 20-ml aliquots were treated with 1 ml benzonase nuclease (purity .99%; 25 U ml
21
; Novagen) for 15 min at 20 uC. Samples were then mixed with an equal volume of 23 SDS sample buffer (125 mM Tris-HCl, 20% (v/v) glycerol pH 6.8 containing 4% (w/v) SDS, 4% (v/v) 2-mercaptoethanol and 0.02% (w/v) bromophenol blue) and immediately transferred to a 100 uC heating block for 10 min. Electrophoresis was performed on 16% Tris-glycine gels (Invitrogen), run for 70 min at 200 V, before electroblotting to Immobilon P membrane (Millipore) for 16 h at 15 V as described previously 34 . Membranes were blocked in phosphate buffered saline (PBS) containing 0.05% (v/v) Tween 20 (PBST) and 5% (w/v) non-fat dried skimmed milk powder. Blots were then probed with anti-human Ab monoclonal antibodies 6E10 (Covance) and 82E1 (IBL international, Hamburg, Germany) at final concentrations of 0.2 mg ml 21 in PBST for at least 1 h. After washing for 1 h with PBST the membranes were probed with a 1:10,000 dilution of alkaline-phosphatase-conjugated goat anti-mouse IgG secondary antibody (Sigma-Aldrich no. A2179) in PBST. After washing (90 min with PBST and 5 min with 20 mM Tris pH 9.8 containing 1 mM MgCl 2 ) blots were incubated for 5 min in chemiluminescent substrate (CDP-Star; Tropix Inc.) and visualized on Biomax MR film (Carestream Health Inc.). Anti-human Ab monoclonal antibody 82E1 recognizes an epitope specific to the amino terminus of Ab while 6E10 recognizes an epitope spanning residues 3-8 of Ab and cross-reacts with full-length APP or APP fragments that contain the epitope.
Examination of prion pathology. In all iCJD cases there was variably prominent microvacuolar change in the neocortices, deep grey nuclei and cerebellar cortex. Immunostaining for the abnormal prion protein revealed synaptic labelling in all grey matter areas examined. In all but one case, there were also microplaques in all grey matter structures. Variability in the intensity of the immunoreactivity for the abnormal prion protein was evident but detailed comparison between the cases and separately within each case was not feasible as prolonged formalin fixation in some cases significantly attenuated the immunoreactivity. It was apparent that more prominent microvacuolar change and synaptic labelling for abnormal prion protein was more intense in the pre-central gyrus and parietal lobe when compared to the anterior frontal and occipital cortices. Deep cortical layers showed more severe changes. In all cases the microvacuolar degeneration and prion protein deposits in the deep grey nuclei and hippocampal formation was prominent. It was most severe in the caudate nucleus and putamen, and appeared less severe in thalamus and it was least prominent in the globus pallidus. In the cerebellar vermis there was marked granule cell atrophy and often widespread loss of Purkinje cells accompanied by severe Bergmann gliosis, while cerebellar hemispherical cortex showed only patchy loss of Purkinje cells and no significant granule cell loss. Microvacuolar degeneration in the molecular layer was more prominent in the vermis than in the cerebellar hemisphere. No apparent difference in prion protein deposition was seen in vermis and hemisphere. In the dentate nucleus variably intense synaptic prion protein immunoreactivity was present, while the cytoarchitecture of the nucleus was well preserved. Examination, classification and quantification of Ab pathology. All brains were examined according to the ABC classification 35 , which assesses the topographic progression of Ab pathology in the brain (Thal phases 36 ), topographic progression of Tau neurofibrillary tangle pathology (Braak and Braak 37 ) and the density of mature (senile), neuritic plaques in the neocortex (Consortium to Establish a Registry for Alzheimer's Disease (CERAD) criteria 38, 39 ). To allow a more detailed assessment of neocortical Ab the original Thal phases were modified as follows. Phase 0, no cortical Ab; phase 0.5, 1-2 neocortical regions affected; phase 1, 3-4 neocortical regions involved; phases 2-5 were scored as published 36 . In addition we have carried out a semiquantitative assessment of neocortical Ab load on a standardised region within frontal, temporal, parietal and occipital lobes, and scored as follows. 0, entirely negative; 1, a single small deposit; 2, multiple small deposits, disseminated; 3, multiple small deposits, plus an area with a larger patch; 4, diffuse moderate numbers of deposits; 5, diffuse, frequent numbers of deposits. For each case a cumulative score (0-20) of total semiquantitatively assessed Ab load in the neocortex was calculated. Cerebral amyloid angiopathy (CAA) was graded (0-3) according to the Vonsattel criteria 3 . CAA was assessed in leptomeninges and parenchyma of all hemispheric lobes and cerebellum with summary score (0-30) calculated for each case. Image acquisition and processing. Histological slides were digitised on a LEICA SCN400F scanner (LEICA Milton Keynes, UK) at 340 magnification and 65% image compression setting during export. Slides were archived and managed on LEICA Slidepath (LEICA Milton Keynes, UK). For the preparation of light microscopy images, 1,024 3 1,024 pixel sized image captures were taken, after matching paired images (Ab and prion staining) in Slidepath, and overlays in Fig. 1f were prepared using the colour conversion function in conjunction with the image overlay in Slidepath. Laser scanning microscopy of double immunofluorescent tissue preparations was on a ZEISS LSM710 confocal microscope (ZEISS Cambridge, UK). Publication figures were assembled in Adobe Photoshop. Data plots were generated using Prism 5 (GraphPad Software, Inc., La Jolla, USA). Digital image analysis for cortical Ab quantification. From all cases Ab immunostained slides from frontal, temporal, parietal and occipital lobes were digitised as described above. Digital image analysis on 496 whole slides was performed using Definiens Developer 2.3 (Definiens, Munich, Germany). Initial tissue identification was performed at a resolution corresponding to 53 image magnification and stain detection was performed at 310 resolution. Tissue detection and initial segmentation was done to identify all tissue within the image, separating the sample from background and non-tissue regions for further analysis. This separation was based on identification of the highly homologous relatively bright/white region of background present at the perimeter of each image. A composite raster image produced by selecting the lowest pixel value from the three comprising colour layers (RGB colour model) provided a greyscale representation of brightness. The mean brightness of this background region was used to exclude all background regions from further analysis.
Stain detection (brown) is based on the transformation of the RGB colour model to a HSD representation 40 . This provides a raster image of the intensity of each colour of interest (brown and blue). A series of dynamic thresholds (T x ) are then used to identify areas of interest (A x ). Initially, following exclusion of intensely stained areas with values greater than 1 arbitrary unit (au) (values range from 0au to 3au in HSD images), the 5th centile (C5) of brown stain intensity was calculated LETTER RESEARCH as a baseline. This represents the T brown stain separating the top 5% of A tissue . The standard deviation (C5d) within the lower 95% of A tissue was used to update the T brown stain as C5z 6|C5d ð Þwith all pixels above this threshold classed as 'stain' (A stain ) and those below as 'unstained' (A unstained ). A stain was excluded if the intensity of blue staining was not significantly lower than the level of brown stain (difference less than 0.1au) to remove generically dark areas. The remaining A stain were further categorised using thresholds based on the mean ( B) and standard deviation (Bd) of brown staining within the A unstained :
Bz 3|Bd ð Þ(lower threshold); T dark brown 5 Bz 6|Bd ð Þ(upper threshold), to give A unstained # T brown . A light brown # T dark brown . A Ab deposit . Artefacts were then identified as A stain with area greater than 1 mm 2 , or an area greater than 0.1 mm 2 with a standard deviation of brown staining below 0.2au. These A artefacts were then expanded to include surrounding pixels with brown staining greater than C5. This excludes large areas of homogenous staining and areas of more diffuse, non-specific chromogen deposit.
The white matter region within the tissue was then manually selected by an expert neuropathologist (Z.J., S.B.). This white matter was excluded from calculation of proportional coverage of A Ab deposit within A tissue .
Extended Data Figure 1 | Vertical scatter plot of Ab pathology in iCJD brain samples, age-matched and older controls. a, CAA summary score as described in Methods. iCJD (age range 36-51) with three highly scoring brain samples with CAA. In the age-matched control groups, no comparable pathology was found. Significant CAA was only seen in a cohort including older individuals carrying the APOE e4 allele. The outlier in the sCJD group (pink triangle in the sCJD . 52 year group) had a surgical intervention 40 years before death, and in addition to CJD also had severe CAA. b, Topographical Ab deposition, assessed according to a scheme modified from the Thal classification as described in the Methods section. In the group of individuals of 51 years and below, significant Ab deposition is seen in the iCJD group, but not in agematched prion diseases of different aetiology. c, Cortical Ab deposition, assessed according to CERAD. In the group of individuals of 51 years and below, mature (neuritic) plaques are seen in the iCJD group, but not in age-matched prion diseases of different aetiology. Only in the cohort comprising much older individuals is there an increase of cortical mature plaques. d, e, Semiquantitative assessment and quantification of neocortical Ab using Definiens Developer image analysis shows a separation that is similar to that shown in a and b. APOE e4 genotype was unavailable in nine of the 85 patients with sCJD and these were not included in the graphs. Note the logarithmic scale in e. In 49 patients from all groups (iCJD, IPD, sCJD and non-CJD) there were variably frequent Ab deposits in the brain parenchyma, corresponding to Thal phases 1-5 (distribution shown on y axis). Of these 49 cases, six cases (IPD n 5 1, sCJD n 5 4, and non-CJD n 5 1) showed Ab deposits also in the pituitary glands (positive cases highlighted in red) and in one patient from sCJD group Ab deposits were seen in the brain tissue attached to the pituitary gland (highlighted in blue).
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